19 results on '"Hisashi, Kaizu"'
Search Results
2. Acute and late toxicities in localized prostate cancer patients treated with low-dose 125I brachytherapy (110 Gy) in combination with external beam radiation therapy versus brachytherapy alone (160 Gy)
- Author
-
Mizuki Sato, Y. Mukai, Narihiko Hayashi, Hiroji Uemura, Hisashi Kaizu, Madoka Sugiura, Masahiro Yao, Shoko Takano, Izumi Koike, Masaharu Hata, and Eiko Ito
- Subjects
0106 biological sciences ,medicine.medical_specialty ,Combination therapy ,medicine.medical_treatment ,Brachytherapy ,Urology ,lcsh:Medicine ,01 natural sciences ,radiation therapy ,Prostate cancer ,medicine ,Radiology, Nuclear Medicine and imaging ,Urethritis ,Rectal hemorrhage ,Genitourinary system ,business.industry ,010401 analytical chemistry ,lcsh:R ,toxicity ,medicine.disease ,prostate cancer ,Low-Dose Rate Brachytherapy ,0104 chemical sciences ,low-dose-rate brachytherapy ,Radiation therapy ,Oncology ,business ,010606 plant biology & botany - Abstract
Purpose The aim of this analysis was to compare acute and late toxicities between low-dose-rate brachytherapy (LDR-BT) (110 Gy) in combination with 45 Gy in 25 fractions external beam radiation therapy (EBRT) and LDR-BT (160 Gy) alone for localized prostate cancer. Material and methods One hundred five consecutive patients with localized prostate cancer treated from May 2014 to May 2017 were included in this retrospective analysis. Sixty patients received combination therapy and 45 patients received BT monotherapy. The LDR-BT procedure was performed using 125I seeds. Results The median follow-up time was 28 months in both groups. Three-year effect rates were overall survival: 100% in both groups. The biochemical failure rate was 2.3% in the combination group and 0% in the monotherapy group (p = 0.373). No patients died during the study period. In both groups, almost all the patients experienced acute urethritis. There was a significant difference between the combination therapy group (8.3%) and BT monotherapy group (11.1%) in late genitourinary (GU) toxicities ≥ grade 2 (p = 0.035). Only 2 patients (3.3%) in the combination therapy group developed late ≥ grade 2 rectal hemorrhage. There were no significant differences between two groups in hematuria ≥ grade 2 (p = 0.068) or rectal hemorrhage ≥ grade 2 (p = 0.206). Conclusions To our knowledge, this is the first report to compare the GU and gastrointestinal toxicities between the combination therapy and BT monotherapy (160 Gy) for localized prostate cancer. Unexpectedly, there were more late GU toxicities (except for hematuria) in the BT monotherapy group.
- Published
- 2018
3. EP307 The role and optimal regimen of radiation therapy for patients with bone metastasis from uterine cervical cancer
- Author
-
Y. Mukai, Madoka Sugiura, Eiko Ito, Masaharu Hata, Mikiko Asai-Sato, Izumi Koike, R. Taniuchi, Etsuko Miyagi, Shoko Takano, M Sato, and Hisashi Kaizu
- Subjects
medicine.medical_specialty ,Chemotherapy ,Palliative care ,business.industry ,medicine.medical_treatment ,Pelvic pain ,Bone metastasis ,medicine.disease ,Primary tumor ,Radiation therapy ,Regimen ,medicine.anatomical_structure ,medicine ,Radiology ,medicine.symptom ,business ,Pelvis - Abstract
Introduction/Background Patients with bone metastasis from uterine cervical cancer usually have a poor prognosis and are candidates for palliative care. We therefore carried out a review to determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and to identify the optimal radiation regimen. Methodology A total of 21 patients with bone metastasis from uterine cervical cancer received radiation therapy to the pelvis. All patients received external irradiation and 13 patients also received high-dose-rate intracavitary brachytherapy. The median total dose of 60.4 Gy (range, 32.4-76.2 Gy) was delivered to cervical tumors of all patients and corresponded to 62.1 Gy (range, 31.9-83.3 Gy) in the 2 Gy per fraction-equivalent dose (EQD2). Thirteen patients underwent chemotherapy during and/or following radiation therapy. Results In 19 of 21 patients, the primary tumors disappeared or were markedly reduced after radiation therapy. In all but one of 18 patients with pelvic pain and bleeding, these symptoms disappeared or were remarkably relieved. However, three patients had primary tumor progression at 7, 9, and 15 months after irradiation with total doses of 56.8, 58.4, and 68.3 Gy in EQD2, respectively. Two of these patients had relapses of bleeding and pain. The primary progression-free rates in all patients were 73% at 1 year, and 37% at 2 years. The overall survival rates were 38% at 1 year, and 9% at 2 years, with an estimated median survival time of 7 months. The number of metastatic bone sites (p=0.016) and administration of chemotherapy (p Conclusion Radiation therapy is very effective for relief of pelvic symptoms in patients with bone metastasis from uterine cervical cancer. For patients who are expected to survive for more than 1 year, almost curative-dose irradiation to primary tumors is recommended. Disclosure Nothing to disclose.
- Published
- 2019
4. Radiation therapy for stage IVA uterine cervical cancer: treatment outcomes including prognostic factors and risk of vesicovaginal and rectovaginal fistulas
- Author
-
Hisashi Kaizu, Eiko Ito, Shoko Takano, Masaharu Hata, Etsuko Miyagi, Madoka Sugiura, Tomio Inoue, Izumi Koike, Reiko Numazaki, Mikiko Asai-Sato, and Y. Mukai
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Radiation proctitis ,cervical cancer ,medicine.medical_treatment ,Gynecologic oncology ,radiation therapy ,Vesicovaginal fistula ,03 medical and health sciences ,0302 clinical medicine ,Obstetrics and gynaecology ,medicine ,Cervical cancer ,Performance status ,business.industry ,medicine.disease ,Surgery ,Radiation therapy ,stage IVA ,Regimen ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,vesicovaginal fistula ,business ,Research Paper ,uterine cervix - Abstract
// Masaharu Hata 1, 2 , Izumi Koike 2 , Etsuko Miyagi 3, 4 , Reiko Numazaki 4, 5 , Mikiko Asai-Sato 4 , Hisashi Kaizu 2 , Yuki Mukai 2 , Shoko Takano 2 , Eiko Ito 2 , Madoka Sugiura 2 and Tomio Inoue 2 1 Division of Radiation Oncology, Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan 2 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan 3 Division of Gynecologic Oncology, Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan 4 Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan 5 Department of Obstetrics and Gynecology, Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan Correspondence to: Masaharu Hata, email: mhata@syd.odn.ne.jp Keywords: cervical cancer; radiation therapy; stage IVA; uterine cervix; vesicovaginal fistula Abbreviations: Biological effective dose, BED; high-dose-rate, HDR; computed tomography, CT; Radiation Therapy Oncology Group, RTOG Received: September 11, 2017 Accepted: October 27, 2017 Published: December 01, 2017 ABSTRACT Purpose: To evaluate the safety and efficacy of radiation therapy for stage IVA uterine cervical cancer and to identify an optimal radiation regimen. Results: Seventeen of the 28 patients developed recurrence after radiation therapy (local recurrence in 10 and distant metastasis in 12). The local control and distant metastasis-free rates at 3 years in all patients were 61% and 49%, respectively. Fourteen patients died after radiation therapy, and all but 2 died of tumor progression. The disease-free, cause-specific, and overall survival rates at 3 years in all patients were 32%, 49%, and 45%, respectively, and the estimated median survival time was 32 months. Tumor size ( P = 0.007) and involvement in the lower third of vagina ( P = 0.006) were significant prognostic factors for local control. Older age ( P = 0.018) and performance status ( P = 0.020) were significant prognostic factors for distant metastasis. The presence of hydronephrosis was the sole significant prognostic factor for survival ( P = 0.026). Only 2 patients developed grade 3 late toxicities (vesicovaginal fistula and radiation proctitis, respectively). Materials and Methods: Twenty-eight patients with stage IVA uterine cervical cancer received radiation therapy. All patients initially received external pelvic irradiation at a median dose of 50.4 Gy in 28 fractions. Twenty patients also received high-dose-rate intracavitary brachytherapy at a median dose of 22 Gy in 4 fractions. These fraction sizes were lower than conventional sizes. The total median dose for all 28 patients was 68.7 Gy. Conclusions: Radiation therapy is safe and effective for treatment of stage IVA uterine cervical cancer. The reduced radiation dose per fraction may contribute to the prevention of vesicovaginal fistula formation.
- Published
- 2017
5. Radiation Therapy for Very Elderly Patients Aged 80 Years and Older With Squamous Cell Carcinoma of the Uterine Cervix
- Author
-
Mikiko Asai-Sato, Tomio Inoue, Hisashi Kaizu, Tonika Matsui, Fumiki Hirahara, Masaharu Hata, T. Kasuya, Izumi Koike, Etsuko Miyagi, and Reiko Numazaki
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Uterine Cervical Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Carcinoma ,Humans ,Basal cell ,Stage (cooking) ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,030219 obstetrics & reproductive medicine ,business.industry ,Intracavitary brachytherapy ,Age Factors ,Retrospective cohort study ,medicine.disease ,Surgery ,Radiation therapy ,Treatment Outcome ,Uterine cervix ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,business - Abstract
We carried out a retrospective review to determine the role played by radiation therapy in the treatment of very elderly patients with uterine cervical cancer. Thirty elderly patients aged 80 years and older with squamous cell carcinoma of the uterine cervix, at clinical stages IB-IVA, underwent radiation therapy. Of these 30 patients, 6 received external irradiation alone and 24 received external irradiation and intracavitary brachytherapy. A total median dose of 69.0 Gy (range, 45.6 to 75.4 Gy) was delivered to the cervical tumors. No patients underwent chemotherapy. At a median follow-up time of 24 months, 7 patients had developed recurrences, including local recurrences in 3 and distant metastases in 5. The local control and distant metastasis-free rates were 88% and 79%, respectively, at 2 years. The disease-free, cause-specific, and overall survival rates were 69%, 77%, and 75%, respectively, at 2 years. Primary tumor size, T category, and clinical stage were found to be significant prognostic factors for distant metastasis. Age and primary tumor size were considered as being significant variables that affected survival. With the exception of a transient hematologic reaction, there were no therapy-related toxicities of grade ≥3. Radiation therapy was safe and effective regarding local control of uterine cervical cancer in elderly patients aged 80 years and older, and appeared to contribute to their prolonged survival. Curative radiation therapy should be considered as a viable treatment option, even in very elderly patients.
- Published
- 2017
6. Outcome of Radiation Therapy for Locally Advanced Vulvar Carcinoma: Analysis of Inguinal Lymph Node
- Author
-
Etsuko Miyagi, Naho Yokota, Eiko Ito, Shoko Takano, Tatsuya Matsunaga, Madoka Sugiura, Hisashi Kaizu, Izumi Koike, Masaharu Hata, and Y. Mukai
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Inguinal lymph nodes ,medicine.medical_treatment ,Locally advanced ,Inguinal Canal ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Tumor stage ,Overall survival ,Medicine ,Humans ,In patient ,Aged ,Retrospective Studies ,Pharmacology ,Aged, 80 and over ,Radiotherapy ,Vulvar Neoplasms ,business.industry ,Middle Aged ,medicine.disease ,Prognosis ,Primary tumor ,Radiation therapy ,Survival Rate ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,Radiology ,Vulvar Carcinoma ,Lymph Nodes ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies ,Research Article - Abstract
Background/Aim: The aim of this study was to define the outcome of radiation therapy for vulvar carcinoma, and to investigate the effectiveness of therapeutic and prophylactic inguinal lymph node (ILN) irradiation. Because reports about the treatment of ILN were limited. Patients and Methods: Thirty consecutive vulvar carcinoma patients were treated using external beam radiation therapy (EBRT) for definitive disease (n=25) or postoperatively (n=5). Twenty-four (80%) had squamous cell carcinoma (SCC). Tumor stages (2002 UICC) ranged from 0 to IVB, with no distant metastases. Results: The median total prescribed dose for primary tumor was 64.8 Gy. The 2-year overall survival rate was 25.3%. The outcome was significantly better in patients with ILNs60 Gy (p=0.002). Conclusions: ILN diameters ≤30 mm and prescribed doses over 60 Gy were associated with ILN control in patients with vulvar carcinoma.
- Published
- 2019
7. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis
- Author
-
Madoka Sugiura, Kazuhide Makiyama, Y. Mukai, Narihiko Hayashi, Hiroji Uemura, Masahiro Yao, Takashi Kawahara, Hisashi Hasumi, Noboru Nakaigawa, Shoko Takano, Eiko Ito, Izumi Koike, Kimito Osaka, Kentaro Muraoka, Keiichi Kondo, Hisashi Kaizu, Koji Izumi, Masaharu Hata, Yasuhide Miyoshi, and Masataka Taguri
- Subjects
Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Brachytherapy ,030232 urology & nephrology ,Logistic regression ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Medicine ,Humans ,Propensity Score ,Aged ,Retrospective Studies ,Prostatectomy ,business.industry ,Cancer ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Radiation therapy ,Survival Rate ,Treatment Outcome ,030220 oncology & carcinogenesis ,Propensity score matching ,T-stage ,Radiotherapy, Intensity-Modulated ,business - Abstract
To compare the outcomes of radical prostatectomy (RP), intensity-modulated radiation therapy (IMRT), and low-dose-rate brachytherapy (BT) using propensity score matching analysis in patients with clinically localized prostate cancer. A group of 2273 patients with clinically localized prostate cancer between January 2004 and December 2015 at the Yokohama City University hospital were identified. The records of 1817 of these patients, who were followed up for a minimum of 2 years, were reviewed; 462 were treated with RP, 319 with IMRT, and 1036 with BT. The patients were categorized according to the National Comprehensive Cancer Network risk classification criteria, and biochemical outcomes and overall survival rates were examined. Biochemical failure for RP was defined as prostate-specific antigen (PSA) levels > 0.2 ng/ml, and for IMRT and BT as nadir PSA level + 2 ng/ml. Propensity scores were calculated using multivariable logistic regression based on covariates, including the patient's age, preoperative PSA, Gleason score, number of positive cores, and clinical T stage. Median follow-up was 77 months for the RP, 54 months for IMRT, and 66 months for BT patients. After the propensity scores were adjusted, a total of 372 (186 each) and 598 (299 each) patients were categorized into RP vs IMRT and RP vs BT groups, respectively. Kaplan–Meier analysis did not show any statistically significant differences in terms of overall survival rate between these groups (RP vs IMRT: p = 0.220; RP vs BT: p = 0.429). IMRT was associated with improved biochemical failure-free survival compared to RP in all risk groups (high-risk: p
- Published
- 2018
8. Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care
- Author
-
Y. Mukai, Shoko Takano, Mikiko Asai-Sato, Tomio Inoue, Izumi Koike, Eiko Ito, Etsuko Miyagi, Masaharu Hata, Hisashi Kaizu, and Madoka Sugiura
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Palliative care ,medicine.medical_treatment ,Brachytherapy ,Uterine Cervical Neoplasms ,Bone Neoplasms ,Adenocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Aged ,Aged, 80 and over ,Cervical cancer ,Chemotherapy ,business.industry ,Pelvic pain ,Palliative Care ,Bone metastasis ,Radiotherapy Dosage ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Primary tumor ,Carcinoma, Neuroendocrine ,Surgery ,Survival Rate ,Radiation therapy ,Regimen ,Oncology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Follow-Up Studies - Abstract
AIM To determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and identify an optimal radiation regimen. PATIENTS AND METHODS A total of 20 patients with bone metastases from uterine cervical cancer received radiation therapy to the pelvis. The median total dose of 60.2 Gy in the 2 Gy per fraction-equivalent dose (EQD2) was delivered to cervical tumors of all patients. Thirteen patients underwent chemotherapy during and/or following radiation therapy. RESULTS In 18 of 20 patients, the primary tumors disappeared or were markedly reduced after radiation therapy. In all but one of 17 patients with pelvic pain and bleeding, these symptoms disappeared or were remarkably relieved. However, three patients had primary tumor progression at 7, 9, and 15 months after irradiation with total doses of 56.8, 58.4, and 68.3 Gy in EQD2, respectively. Two of these patients had relapses of bleeding and pain. The primary progression-free rate considering all patients was 69% at 1 year and 34% at 2 years. The corresponding overall survival rates were 34% at 1 year, and 8% at 2 years, with an estimated median survival time of 7 months. The number of metastatic bone sites (p=0.027) and administration of chemotherapy (p
- Published
- 2018
9. Postoperative radiation therapy for extramammary Paget's disease
- Author
-
Hidefumi Wada, Masaharu Hata, Tomio Inoue, Izumi Koike, Etsuko Miyagi, T. Kasuya, Hisashi Kaizu, and Y. Mukai
- Subjects
Male ,medicine.medical_specialty ,Genital Neoplasms, Female ,medicine.medical_treatment ,Dermatology ,Disease ,Perineum ,Extramammary Paget's disease ,medicine ,Adjuvant therapy ,Humans ,Aged ,Aged, 80 and over ,Postoperative Care ,business.industry ,Postoperative radiation ,Middle Aged ,medicine.disease ,Surgery ,Radiation therapy ,Pneumonia ,Paget Disease, Extramammary ,Treatment Outcome ,Total dose ,Genital Neoplasms, Male ,Female ,Radiotherapy, Adjuvant ,Positive Surgical Margin ,business - Abstract
SummaryBackground Extramammary Paget's disease (EMPD) is a rare cutaneous malignancy that is usually treated with surgery. Patients with positive surgical margins require adjuvant therapy, but there have been few reports on the use of radiation therapy. Objectives To investigate the effectiveness of postoperative radiation therapy in EMPD. Materials and methods Twenty-one patients with EMPD involving the genitalia underwent radiation therapy as adjuvant therapy after surgery. Ten patients had inguinal lymph node involvement before radiation therapy, but none had distant metastases. A median total dose of 59·4 Gy (range, 45–64·8 Gy) was delivered to the tumour bed in 30 fractions (range, 23–36 fractions). Results At a median follow-up period of 38 months, all patients had local control. However, six patients had developed distant metastases 6–43 months after radiation therapy. The distant metastasis-free rates were 66% at 3 years and 55% at 5 years. Inguinal lymph node involvement was a significant risk factor for distant metastases. Four patients died 33–58 months after irradiation; the causes of death were tumour progression in three patients and infectious pneumonia in one. The overall and cause-specific survival rates were both 92% at 3 years, and 62% and 71% at 5 years, respectively. No therapy-related toxicities of grade ≥ 3 were observed. Conclusions Postoperative radiation therapy is safe and effective in maintaining local control in patients with EMPD.
- Published
- 2015
10. Retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab for carcinoma of the buccal mucosa with N3 lymph node metastasis: a case report
- Author
-
Jun Ueda, Kenji Mitsudo, Iwai Tohnai, Yuichiro Hayashi, Masaharu Hata, Kaname Sakuma, Haruka Yoshii, Toshiyuki Koizumi, Akira Tanaka, Makoto Hirota, Toshinori Iwai, Mitomu Kioi, and Hisashi Kaizu
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Cetuximab ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Carcinoma ,Humans ,Infusions, Intra-Arterial ,Radiology, Nuclear Medicine and imaging ,Dentistry (miscellaneous) ,Lymph node ,business.industry ,Mouth Mucosa ,Neck dissection ,030206 dentistry ,Chemoradiotherapy ,Hyperthermia, Induced ,Middle Aged ,medicine.disease ,Primary tumor ,Radiation therapy ,medicine.anatomical_structure ,Docetaxel ,Lymphatic Metastasis ,Mouth Neoplasms ,Radiology ,Lymph Nodes ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
We herein report a case of squamous cell carcinoma of the buccal mucosa with N3 cervical lymph node metastasis in a 63-year-old man. The patient was treated with combination therapy comprising radiotherapy (2 Gy/day, total of 70 Gy), superselective intra-arterial chemotherapy via a superficial temporal artery (docetaxel, total of 70 mg/m2 and cisplatin, total of 175 mg/m2), cetuximab (initial dose of 400 mg/m2 with subsequent weekly doses of 250 mg/m2 intravenously), and four sessions of hyperthermia for cervical lymph node metastases. The patient responded well to the therapy, with a complete response of the primary tumor. Radical neck dissection was performed with reconstructive surgery, including resection of the overlying skin. A pathologic complete response was achieved for the N3 and all other cervical lymph node metastases. The patient showed no evidence of recurrence in the 3 years following treatment. Based on the findings in the present case, the use of retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab seems to be a promising modality for patients with N3 cervical lymph node metastasis of oral cancer.
- Published
- 2017
11. Outcome of Postoperative Radiation Therapy for Cholangiocarcinoma and Analysis of Dose-Volume Histogram of Remnant Liver
- Author
-
Y. Mukai, Itaru Endo, Masaharu Hata, T. Kumamoto, Hisashi Kaizu, Izumi Koike, R. Matsuyama, and Y. Homma
- Subjects
Remnant liver ,Cancer Research ,Dose-volume histogram ,medicine.medical_specialty ,Radiation ,Oncology ,business.industry ,Postoperative radiation ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,business - Published
- 2019
12. Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
- Author
-
Shoko Takano, Ryusei Matsuyama, Madoka Sugiura, Mizuki Sato, Izumi Koike, Hisashi Kaizu, Itaru Endo, Yuki Homma, Yasuhiro Yabushita, Eiko Ito, Takafumi Kumamoto, Masaharu Hata, Yu Sawada, and Y. Mukai
- Subjects
Radiation-Sensitizing Agents ,Dose-volume histogram ,Pyridines ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Deoxycytidine ,Gastroenterology ,Cholangiocarcinoma ,Liver disease ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,030212 general & internal medicine ,Aged, 80 and over ,biology ,Liver Diseases ,Liver Neoplasms ,Radiotherapy Dosage ,Common Terminology Criteria for Adverse Events ,General Medicine ,Middle Aged ,Combined Modality Therapy ,Drug Combinations ,030220 oncology & carcinogenesis ,Toxicity ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Research Article ,Adult ,medicine.medical_specialty ,Observational Study ,Aspartate transaminase ,remnant liver ,03 medical and health sciences ,Internal medicine ,medicine ,Hepatectomy ,Humans ,Radiation Injuries ,dose-volume histogram ,Aged ,Neoplasm Staging ,Tegafur ,business.industry ,medicine.disease ,Gemcitabine ,Radiation therapy ,Oxonic Acid ,Alanine transaminase ,radiation-induced liver disease ,biology.protein ,Radiotherapy, Adjuvant ,postoperative-radiation therapy ,Cisplatin ,Tomography, X-Ray Computed ,business - Abstract
Supplemental Digital Content is available in the text, The aim of this study was to analyze dose-volume histogram (DVH) of the remnant liver for postoperative cholangiocarcinoma (CCA) patients, to find toxicity rates, and to confirm efficacy of postoperative radiation therapy (RT). Thirty-two postoperative CCA patients received partial liver resection and postoperative RT with curative intent. The “liver reduction rate” was calculated by contouring liver volume at computed tomography (CT) just before the surgery and at CT for planning the RT. To evaluate late toxicity, the radiation-induced hepatic toxicity (RIHT) was determined by the common terminology criteria for adverse events toxicity grade of bilirubin, aspartate transaminase, alanine transaminase, alkaline phosphatase, and albumin, and was defined from 3 months after RT until liver metastasis was revealed. The radiation-induced liver disease (RILD) was also evaluated. Tumor stages were distributed as follows: I: 1, II: 8, IIIA: 1, IIIB: 6, IIIC: 14, IVA: 2. Median prescribed total dose was 50 Gy. Median follow-up time was 27 months. Two-year overall survival (OS): 72.4%, disease-free survival: 47.7%, local control: 65.3%, and the median survival time was 40 months. The median “liver reduction rate” was 21%. The OS had statistically significant difference in nodal status (P = .032) and “liver reduction rate” >30% (P = .016). In the association between the ≥grade 2 RIHT and DVH, there were significantly differences in V30 and V40 (P = .041, P = .034), respectively. The grade ≥2 RIHT rates differ also significantly by sex (P = .008). Two patients (6.2%) were suspected of RILD. We suggest that RT for remnant liver should be considered the liver V30, V40 to prevent radiation-induced liver dysfunction.
- Published
- 2019
13. Radiation Therapy for Sebaceous Carcinoma of the Eyelid: Tumor Control and Preservation of Visual Function
- Author
-
N. Mizuki, R. Taniuchi, Madoka Sugiura, Tomio Inoue, Hisashi Kaizu, Eiko Ito, Shoko Takano, Izumi Koike, Jiro Maegawa, Y. Mukai, Masaharu Hata, and A. Kaneko
- Subjects
Cancer Research ,medicine.medical_specialty ,Radiation ,business.industry ,medicine.medical_treatment ,medicine.disease ,Tumor control ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,Visual function ,medicine ,Radiology, Nuclear Medicine and imaging ,Eyelid ,Radiology ,business ,Sebaceous carcinoma - Published
- 2018
14. Radiation therapy for pelvic lymph node metastasis from uterine cervical cancer
- Author
-
Reiko Numazaki, T. Kasuya, Tonika Matsui, Fumiki Hirahara, Masaharu Hata, Etsuko Miyagi, Mikiko Asai-Sato, Tomio Inoue, Hisashi Kaizu, and Izumi Koike
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Ileus ,medicine.medical_treatment ,Perforation (oil well) ,Uterine Cervical Neoplasms ,Disease-Free Survival ,Pelvis ,Young Adult ,Internal medicine ,medicine ,Humans ,Lymph node ,Aged ,Aged, 80 and over ,Cervical cancer ,Radiotherapy ,business.industry ,Carcinoma ,Obstetrics and Gynecology ,Sigmoid colon ,Anemia ,Chemoradiotherapy ,Leukopenia ,Middle Aged ,medicine.disease ,Thrombocytopenia ,Survival Rate ,Radiation therapy ,Intestinal Diseases ,Regimen ,medicine.anatomical_structure ,Lymphatic Metastasis ,Disease Progression ,Female ,Dose Fractionation, Radiation ,Lymph ,Radiology ,business - Abstract
This study aimed to evaluate the efficacy of radiation therapy for pelvic lymph node metastasis from uterine cervical cancer and identify an optimal radiation regimen.A total of 111 metastatic pelvic lymph nodes, ranging from 11 to 56 mm (median, 25 mm) on CT/MRI, in 62 patients with uterine cervical cancer were treated initially with curative radiation therapy, with 46 patients receiving concurrent chemotherapy. Total radiation doses ranged from 45 to 61.2 Gy (median, 50.4 Gy) in 1.8-2 Gy (median, 1.8 Gy) fractions.At a median follow-up of 33 months, 46 of the 62 patients survived. Only 2 irradiated lymph nodes, 24 and 28 mm in diameter, in 1 patient progressed after irradiation alone with 50.4 Gy in 1.8 Gy fractions. All 33 metastatic lymph nodes ≥ 30 mm in diameter were controlled by irradiation at a median dose of 55.8 Gy. The 3-year lymph node-progression free rates were 98.2% in all 62 patients and 98.0% in all 111 metastatic lymph nodes. Except for transient hematologic reactions, 2 patients developed grade ≥ 3 therapy-related toxicities, 1 with an ulcer and the other with perforation of the sigmoid colon. In addition, 2 patients experienced ileus after irradiation.Radiation therapy effectively controlled pelvic lymph node metastases in patients with uterine cervical cancer, with most nodes24 mm in diameter controlled by total doses of 50.4 Gy in 1.8 Gy fractions and larger nodes controlled by 55.8 Gy, particularly with concurrent chemotherapy. Higher doses to metastatic lymph nodes may increase intestinal toxicities.
- Published
- 2013
15. Safety and Efficacy of Radiation Therapy for Very Elderly Patients Aged 80 Years or Older with Uterine Cervical Cancer
- Author
-
Mikiko Asai-Sato, Y. Mukai, Tomio Inoue, Masaharu Hata, Izumi Koike, Madoka Sugiura, Reiko Numazaki, Hisashi Kaizu, Shoko Takano, Etsuko Miyagi, and Eiko Ito
- Subjects
Radiation therapy ,Oncology ,Cancer Research ,medicine.medical_specialty ,Radiation ,Uterine cervical cancer ,business.industry ,medicine.medical_treatment ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,business - Published
- 2017
16. Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors
- Author
-
Hisashi Kaizu, Etsuko Miyagi, Y. Mukai, Tomio Inoue, Izumi Koike, T. Matsui, Eiko Ito, Hidefumi Wada, Masaharu Hata, and T. Kasuya
- Subjects
Oncology ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Treatment outcome ,Disease ,Kaplan-Meier Estimate ,Malignancy ,Extramammary Paget's disease ,Internal medicine ,Medicine ,Humans ,Lymph node ,Aged ,Aged, 80 and over ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Radiation therapy ,Pneumonia ,medicine.anatomical_structure ,Paget Disease, Extramammary ,Treatment Outcome ,Tumor progression ,Female ,Radiotherapy, Adjuvant ,Radiology ,Dose Fractionation, Radiation ,business ,Urogenital Neoplasms - Abstract
Background Extramammary Paget's disease (EMPD) is a relatively rare malignancy, and there are few reports related to radiation therapy. In the present study, we investigated the outcome of radiation therapy for EMPD. Patients and methods Forty-one patients with EMPD in the genitalia underwent radiation therapy with curative intent. Fifteen patients had regional lymph node metastases before radiation therapy, but none had distant metastasis. Total doses of 45–80.2 Gy (median, 60 Gy) were delivered to tumor sites in 23–43 fractions (median, 33 fractions). Results At a median follow-up period of 41 months, 16 patients had developed recurrences, including 5 with local progression within the radiation field and 12 with lymph node or/and distant metastases outside the radiation field. The local progression-free and disease-free rates were 88% and 55% at 3 years, and 82% and 46% at 5 years, respectively. Nine patients died at 6–73 months after irradiation; the causes of death were tumor progression in five patients, infectious pneumonia in two, renal failure in one and old age in one. The overall and cause-specific survival rates were 93% and 96% at 3 years, and 68% and 84% at 5 years, respectively. Tumor invasion into the dermis and regional lymph node metastasis were significant prognostic factors for both distant metastasis and survival. No therapy-related toxicities of grade ≥3 were observed. Conclusions Radiation therapy is safe and effective for patients with EMPD. It appeared to contribute to prolonged survival owing to good tumor control, and to be a promising curative treatment option.
- Published
- 2013
17. EP-1345: Radiation therapy for pelvic lymph node metastasis from uterine cervical cancer
- Author
-
Tomio Inoue, Izumi Koike, T. Matsui, T. Kasuya, Reiko Numazaki, Hisashi Kaizu, Etsuko Miyagi, Mikiko Asai-Sato, Fumiki Hirahara, and Masaharu Hata
- Subjects
Radiation therapy ,Oncology ,medicine.medical_specialty ,Uterine cervical cancer ,business.industry ,medicine.medical_treatment ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,Lymph node metastasis ,business - Published
- 2014
18. Radiation Therapy for Extramammary Paget Disease: Treatment Outcomes and Prognostic Factors
- Author
-
R. Suzuki, Hisashi Kaizu, Yumiko Minagawa, Masaharu Hata, Y. Mukai, Tomio Inoue, Izumi Koike, T. Matsui, T. Kasuya, and Shoko Takano
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Radiation ,business.industry ,medicine.medical_treatment ,Treatment outcome ,Radiation therapy ,Internal medicine ,Paget Disease ,Medicine ,Radiology, Nuclear Medicine and imaging ,business - Published
- 2013
19. Radiation Therapy for Primary Carcinoma of the Eyelid: Tumor Control and Visual Function
- Author
-
Y. Mukai, Hisashi Kaizu, K. Odagiri, Jiro Maegawa, Yumiko Minagawa, Masaharu Hata, A. Kaneko, T. Kasuya, Tomio Inoue, and Izumi Koike
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Visual acuity ,Esthetics ,medicine.medical_treatment ,Kaplan-Meier Estimate ,In Vitro Techniques ,Eyelid Neoplasms ,Radiation Protection ,Cataracts ,Cause of Death ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,Eyelid Carcinoma ,Basal cell carcinoma ,Vision, Ocular ,Survival analysis ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Radiation ,Blinking ,business.industry ,Adenocarcinoma, Sebaceous ,Eyelids ,Middle Aged ,medicine.disease ,eye diseases ,Surgery ,Survival Rate ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,Carcinoma, Basal Cell ,Carcinoma, Squamous Cell ,Female ,Radiotherapy, Adjuvant ,Eyelid ,medicine.symptom ,business ,Follow-Up Studies ,Sebaceous carcinoma - Abstract
Surgical excision remains the standard and most reliable curative treatment for eyelid carcinoma, but frequently causes functional and cosmetic impairment of the eyelid. We therefore investigated the efficacy and safety of radiation therapy in eyelid carcinoma. Twenty-three patients with primary carcinoma of the eyelid underwent radiation therapy. Sebaceous carcinoma was histologically confirmed in 16 patients, squamous cell carcinoma in 6, and basal cell carcinoma in 1. A total dose of 50–66.6 Gy (median, 60 Gy) was delivered to tumor sites in 18–37 fractions (median, 30 fractions). All but 3 of the 23 patients had survived at a median follow-up period of 49 months. The overall survival and local progression-free rates were 87% and 93% at 2 years, and 80% and 93% at 5 years, respectively. Although radiation-induced cataracts developed in 3 patients, visual acuity in the other patients was relatively well preserved. There were no other therapy-related toxicities of grade 3 or greater. Radiation therapy is safe and effective for patients with primary carcinoma of the eyelid. It appears to contribute to prolonged survival as a result of good tumor control, and it also facilitates functional and cosmetic preservation of the eyelid.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.